HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial.

AuthorsZhitao Ying, Dehui Zou, Haiyan Yang, Jianqiu Wu, Ye Guo, Wenyu Li, Hui Liu, Chris Wang, Laura Ma, Su Yang, Zisong Zhou, Yun Qin, Yuqin Song, Jun Zhu
JournalAmerican journal of hematology (Am J Hematol) Vol. 97 Issue 12 Pg. E436-E438 (12 2022) ISSN: 1096-8652 [Electronic] United States
PMID36053875 (Publication Type: Clinical Trial, Phase II, Clinical Trial, Phase I, Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • relmacabtagene autoleucel
  • Rituximab
Topics
  • Adult
  • Humans
  • Lymphoma, Follicular (drug therapy)
  • Rituximab
  • Lymphoma, Non-Hodgkin (pathology)
  • China
  • Neoplasm Recurrence, Local

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: